Keyphrases
Treatment Outcome
100%
Imatinib Mesylate
100%
Gastrointestinal Stromal Tumor
100%
Positron Emission tomography-CT
100%
Positron Emission Tomography
90%
Contrast Enhancement
80%
Helical Computed Tomography
80%
Computational Imaging
30%
Tumor Patients
20%
Prognostic Power
20%
Fluorodeoxyglucose Uptake
20%
Clinical Decision-making
10%
Chemotherapy
10%
Treatment Response
10%
Switzerland
10%
Surgical Intervention
10%
Sarcoma
10%
Median Overall Survival
10%
Clinical Role
10%
Prognostic Information
10%
Prognostic Significance
10%
Better Prognosis
10%
Time-to-treatment
10%
Treatment Duration
10%
Time to Progression
10%
Tyrosine Kinase Inhibitor
10%
Novartis
10%
Active Lesions
10%
Functional Method
10%
Start of Treatment
10%
Restaging
10%
Tomography Image
10%
18F-fluorodeoxyglucose (18F-FDG)
10%
Overall Survival Time
10%
Computed Tomography Images
10%
Gleevec
10%
Mesenchymal Neoplasm
10%
CT Examination
10%
Gastrointestinal Neoplasms
10%
Residual Activity
10%
Medicine and Dentistry
Imatinib
100%
Positron Emission Tomography
100%
Gastrointestinal Stromal Tumor
100%
Spiral Computed Tomography
42%
Fluorodeoxyglucose
10%
Connective Tissue Cancer
10%
Overall Survival
5%
Chemotherapy
5%
Treatment Duration
5%
Treatment Response
5%
Tyrosine-Kinase Inhibitor
5%
Survival Time
5%
Fluorodeoxyglucose F 18
5%
Gastrointestinal Tract
5%
Surgery
5%
Clinical Decision Making
5%
Pharmacology, Toxicology and Pharmaceutical Science
Imatinib
100%
Gastrointestinal Stromal Tumor
100%
Fluorodeoxyglucose
40%
Connective Tissue Cancer
40%
Chemotherapy
20%
Overall Survival
20%
Protein Tyrosine Kinase Inhibitor
20%
Fluorodeoxyglucose F 18
20%
Survival Time
20%